Daily ReportNov 6, 2026
Sepsis, November 6 edition
We read 46 papers and selected 3.
Summary
Today’s most impactful sepsis research spans a rigorous negative multicenter randomized trial, a mechanistic discovery defining toxin-induced innate immune memory, and a prospective proteomic diagnostic study. Together, these papers emphasize that sepsis advances require both treatment de-escalation when efficacy is absent and biologically informed approaches to diagnosis and host-directed therapy.
Research Themes
- Negative randomized evidence for adjunctive sepsis therapy
- Toxin-induced innate immune memory and host resistance
- Prospective proteomic biomarker development for early diagnosis
Selected Articles
1. Bacterial toxin sensing induces transient inflammasome-dependent innate immune memory that improves survival during sepsis.
Using in vitro and in vivo mouse models together with primary human macrophages, the study demonstrated that bacterial toxins can induce transient trained immunity through NLRP3 inflammasome activation. CNF1-induced epigenetic remodeling required Bcl2a1 and IL-1 signaling, and toxin-induced trained immunity improved resistance and survival in experimental sepsis.
Impact: This study provides a mechanistic demonstration that bacterial toxins can generate protective innate immune memory, extending the concept of host memory beyond adaptive immunity. It identifies a potentially exploitable pathway for host-directed sepsis prevention while also highlighting the need to control inflammatory risks.
Clinical Implications: The findings do not support immediate clinical use of bacterial toxins, but they provide a rationale for developing safer toxin-derived immunomodulators or vaccination strategies. Translation will require confirmation in human longitudinal studies and careful assessment of pathogen-specific and inflammatory consequences.
Key Findings
- CNF1 and other bacterial toxins induced trained immunity through NLRP3 inflammasome activation in vitro and in vivo.
- CNF1 exposure caused epigenetic remodeling and established a trained-immunity transcriptional signature in macrophages.
- Bcl2a1 and IL-1 signaling were required for the response, and toxin-induced trained immunity improved survival in a mouse sepsis model.
Methodological Strengths
- Validation across complementary in vitro, murine in vivo, and primary human macrophage systems
- Mechanistic dissection using targeted RNA interference, epistasis analysis, and epigenetic profiling
Limitations
- The survival benefit was demonstrated in experimental mouse sepsis models and has not been established in human sepsis.
- The durability, specificity, and safety of toxin-induced trained immunity remain incompletely defined.
Future Directions: Future work should identify safer molecular mimetics of the CNF1 response, define the human immune-cell states that predict benefit, and test whether transient trained immunity can improve infection outcomes without increasing tissue injury or secondary inflammatory disease.
Adaptive immune memory generated by bacterial toxin vaccination is well established, but whether bacterial toxins can also induce innate immune memory, or trained immunity (TI), remains unclear. Here, we show that bacterial toxins elicit TI through NLRP3 inflammasome activation both in vitro and in vivo in mice. Stimulation with the CNF1 toxin induced an epigenetic remodeling, defining a TI-associated transcriptional signature.
2. Efficacy and Safety of Ulinastatin in the Treatment of Patients with Sepsis: The ADJUST Trial.
In this multicenter, randomized, double-blind, placebo-controlled trial, adjunctive ulinastatin did not reduce 28-day mortality compared with placebo. Mortality was 23.6% with ulinastatin versus 22.9% with placebo, while adverse events were significantly more frequent with ulinastatin.
Impact: The ADJUST trial provides high-quality evidence against routine adjunctive ulinastatin use in sepsis. Its negative result is clinically important because it challenges prior signals of benefit and supports avoiding an ineffective therapy associated with additional adverse events.
Clinical Implications: Routine adjunctive ulinastatin should not be used to reduce mortality in adult patients with sepsis based on these findings. Clinicians should prioritize evidence-based standard care and reserve further ulinastatin use for appropriately designed research settings.
Key Findings
- Among 335 patients in the intention-to-treat population, 28-day mortality was 23.6% with ulinastatin and 22.9% with placebo.
- Ulinastatin did not improve secondary outcomes, including ICU, hospital, or 90-day mortality.
- Adverse events occurred in 56.8% of ulinastatin-treated patients versus 42.7% of placebo-treated patients.
Methodological Strengths
- Multicenter randomized, double-blind, placebo-controlled design with stratification by site and septic shock
- Prespecified mortality endpoints and intention-to-treat analysis with prospective clinical trial registration
Limitations
- The study was not designed to identify biological or clinical subgroups that might benefit from ulinastatin.
- The findings apply to the studied dose, treatment duration, and adult ICU population and may not generalize to other regimens or populations.
Future Directions: Future research should focus on biomarker-guided selection of immunomodulatory therapies, prespecified enrichment strategies, and comparative effectiveness studies rather than empiric routine use of ulinastatin in unselected sepsis populations.
BACKGROUND: Urinary trypsin inhibitor (ulinastatin, UTI) has shown potential survival benefits in sepsis; however, conclusive clinical evidence is lacking. RESEARCH QUESTION: In patients with sepsis, does adjunctive ulinastatin, compared with placebo, reduce 28-day all-cause mortality? STUDY DESIGN AND METHODS: In this multicenter, randomized, double-blind, placebo-controlled trial, adult ICU patients with sepsis meeting Sepsis-3 criteria within 48 hours of admission were randomized (1:1) to receive intravenous UTI (400,000 IU every 8 hours) or placebo, for up to 10 days in addition to standard care.
3. Proteomics Reveals Novel Biomarkers in the Blood for Sepsis Diagnosis.
A multiphase proteomic workflow identified AHSG, clusterin, and kallistatin as consistently downregulated blood proteins in sepsis. A random forest model based on these three proteins achieved an AUC of 0.87 in a prospective cohort of 143 patients with suspected sepsis and outperformed procalcitonin and C-reactive protein.
Impact: The study advances sepsis diagnosis by combining discovery proteomics, targeted verification, immunoassay confirmation, and prospective clinical testing. The prospective performance assessment makes the biomarker panel more translationally relevant than a discovery-only proteomic signature.
Clinical Implications: If externally validated, the three-protein panel could complement existing biomarkers for earlier sepsis recognition and risk stratification. It should not yet replace clinical assessment, microbiology, or established biomarkers because implementation performance, calibration, assay turnaround, and effects on patient outcomes remain unproven.
Key Findings
- AHSG, clusterin, and kallistatin were consistently downregulated across discovery and verification cohorts.
- A random forest model combining the three proteins achieved an apparent AUC of 0.94 in training and an AUC of 0.87 in a prospective cohort of 143 patients with suspected sepsis.
- The panel significantly outperformed procalcitonin and C-reactive protein and classified 73.0% of confirmed sepsis cases as high-risk.
Methodological Strengths
- Multiphase workflow linking untargeted discovery, targeted parallel-reaction-monitoring verification, ELISA confirmation, and machine learning
- Prospective clinical evaluation rather than relying solely on retrospective discovery cohorts
Limitations
- The prospective validation cohort included 143 suspected-sepsis patients and requires larger, multicenter external validation.
- The abstract does not establish whether the biomarker panel improves treatment decisions, time to antibiotics, or patient outcomes.
Future Directions: Future studies should perform blinded multicenter validation across diverse infection sources and noninfectious inflammatory conditions, establish rapid standardized assays, assess calibration and clinical utility, and evaluate whether biomarker-guided pathways improve patient-centered outcomes.
Early sepsis diagnosis in critically ill patients remains a major unmet need. We employed a multiphase proteomic strategy integrating discovery by data-independent acquisition, targeted verification by parallel reaction monitoring, clinical confirmation with ELISA, and machine learning to identify robust blood biomarkers. In discovery and verification cohorts, three consistently downregulated proteins, α-2-HS-glycoprotein (AHSG), clusterin (CLU), and kallistatin (SERPINA4), were prioritized.